Skip to main content
SpringerLink
Log in

Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

  • ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

IgA antiphospholipid antibodies (aPL) are not currently recognized as formal laboratory criteria for the Antiphospholipid Syndrome (APS). This is mainly due to methodological issues (different study designs, use of various non-standardized IgA assays). However, there are experimental data showing the pathogenic role of IgA anti-cardiolipin antibodies (aCL) and IgA anti-β2glycoprotein I antibodies (anti-β2GPI). Isolated IgA aCL are not very common, therefore their testing could be useful in the case of strong suspicion of APS but negative results for other aPL tests. IgA anti-β2GPI seem to be the most prevalent isotype in patients with Systemic Lupus Erythematosus (SLE), with a significant association with thrombotic events. Such a clinical relevance has been recently recognized by the inclusion of these autoantibodies among the aPL tests in the novel SLICC classification criteria for SLE. Emerging interest has been raised by IgA anti-β2GPI against domain 4/5 as a novel subgroup of clinically relevant aPL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis. 2006;295–306.

  2. •• Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191–205. The literature on ‘non-criteria’ aPL (including IgA aPL) has been reviewed in an evidence-based manner by a task force of worldwide scientists. Findings, conclusions and recommendations are summarized in this report.

    Article  PubMed  CAS  Google Scholar 

  3. •• Lakos G, Favaloro EJ, Harris EN, et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012;64(1):1–10. This is the most up-to-date and detailed report on the consensus guidelines on the recommended best practices for immunoassays for the measurement of aCL and anti-β2GPI antibodies.

    Article  PubMed  Google Scholar 

  4. • Meijide H, Sciascia S, Sanna G, et al. The clinical relevance of IgA anticardiolipin and IgA anti-β2 glycoprotein I antiphospholipid antibodies: A systematic review. Autoimmun Rev. 2012 [Epub ahead of print]. A comprehensive review of the literature on IgA aPL between January 1990 and April 2012. Relevant articles have been divided and analyzed in 3 subgroups: (1) studies that showed usefulness of IgA aPL testing in autoimmune population; (2) studies with no clinical associations of IgA aPL in autoimmune population; and (3) studies of IgA aPL in other non-autoimmune disorders.

  5. Uthman I, Khamashta M. Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis. 2005;64:1671–6.

    Article  PubMed  CAS  Google Scholar 

  6. Weidmann CE, Wallace DJ, Peter JB, et al. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol. 1988;15:74–9.

    PubMed  CAS  Google Scholar 

  7. Kalunian KC, Peter JB, Middlekauff HR, et al. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 1988;85:602–8.

    Article  PubMed  CAS  Google Scholar 

  8. Alarcón-Segovia D, Delezé M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore). 1989;68:353–65.

    Google Scholar 

  9. Lopez LR, Santos M, Espinoza LR, et al. Clinical significance of Immunoglobulin A versus Immnunoglobulin G and M Anticardiolipin antibodies in Patients with Systemic Lupus Erythematosus: correlation with thrombosis, thrombocytopenia and recurrent abortion. Coag Transf Med. 1991;98:449–54.

    Google Scholar 

  10. Molina JF, Gutierrez-Ureña S, Molina J, et al. Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol. 1997;24:291–6.

    PubMed  CAS  Google Scholar 

  11. Tajima C, Suzuki Y, Mizushima Y, Ichikawa Y. Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol. 1998;25:1730–6.

    PubMed  CAS  Google Scholar 

  12. Cucurull E, Gharavi AE, Diri E, et al. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci. 1999;318:55–60.

    Article  PubMed  CAS  Google Scholar 

  13. Hanly JG, Hong C, Smith S, et al. A prospective analysis of cognitive dysfunction and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999;42:728–34.

    Article  PubMed  CAS  Google Scholar 

  14. Sebastiani GD, Galeazzi M, Tincani A, et al. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol. 1999;28:344–51.

    Article  PubMed  CAS  Google Scholar 

  15. Samarkos M, Davies KA, Gordon C, et al. Clinical significance of IgA anticardiolipin and anti-β2-GPI antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25:199–204.

    Article  PubMed  CAS  Google Scholar 

  16. Shen YM, Lee R, Frenkel E, Sarode R. IgA antiphospholipid antibodies are an independent risk factor for thromboses. Lupus. 2008;17:996–1003.

    Article  PubMed  CAS  Google Scholar 

  17. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis. 1987;46:1–6.

    Article  PubMed  CAS  Google Scholar 

  18. Wong KL, Liu HW, Ho K, et al. Anticardiolipin antibodies and Lupus anticoagulant in Chinese patients with systemic lupus erythematosus. J Rheumatol. 1991;18:1187–92.

    PubMed  CAS  Google Scholar 

  19. Loizou S, Cofiner C, Weetman AP, et al. Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol. 1992;90:434–9.

    Article  PubMed  CAS  Google Scholar 

  20. Merkel PA, Chang YC, Pierangeli S, et al. The Prevalence and Clinical Associations of Anticardiolipin Antibodies in a Large Inception Cohort of Patients with Connective Tissue Diseases. Am J Med. 1996;101:576–83.

    Article  PubMed  CAS  Google Scholar 

  21. Selva-O'Callaghan A, Ordi-Ros J, Monegal-Ferran F, et al. IgA anticardiolipin antibodies–relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost. 1998;79:282–5.

    PubMed  Google Scholar 

  22. Fanopoulos D, Teodorescu MR, Varga J, et al. High frequency of abnormal levels of IgA anti-beta-glycoprotein I in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol. 1998;25:675–850.

    PubMed  CAS  Google Scholar 

  23. Lakos G, Kiss E, Regéczy N, et al. Isotype distribution and clinical relevance of anti-β2-glycoprotein I (β2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999;117:574–9.

    Article  PubMed  CAS  Google Scholar 

  24. Greco TP, Amos MD, Conti-Kelly AM, et al. Testing for the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I. Lupus. 2000;9:33–41.

    Article  PubMed  CAS  Google Scholar 

  25. Spadaro A, Riccieri V, Terracina S, et al. Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus. 2000;9:56–60.

    Article  PubMed  CAS  Google Scholar 

  26. Shrivastava A, Dwivedi S, Aggarwal A, et al. Anti-cardiolipin and anti-beta 2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: association with the presence of seizure. Lupus. 2001;10:45–50.

    Article  PubMed  CAS  Google Scholar 

  27. Bertolaccini ML, Atsumi T, Escuedero Contreras A, et al. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol. 2001;28:2637–43.

    PubMed  CAS  Google Scholar 

  28. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001;185:748–53.

    Article  PubMed  CAS  Google Scholar 

  29. Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, et al. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis. 2003;62:540–3.

    Article  PubMed  CAS  Google Scholar 

  30. • Mehrani T, Petri M. Association of IgA Anti-β2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. J Rheumatol. 2011;38:64–8. In a large cohort of SLE patients, it has been demonstrated that IgA anti-β2GPI antibodies are associated with venous thrombosis and other clinical and laboratory features typical of SLE and APS.

    Article  PubMed  Google Scholar 

  31. Diri E, Cucurull E, Gharavi AE, et al. Antiphospholipid (Hughes’) syndrome in african-americans: IgA aCl and aβ2 glycoprotein-I is the most frequent isotype. Lupus. 1999;8:263–8.

    Article  PubMed  CAS  Google Scholar 

  32. Picillo U, Migliaresi S, Marcialis MR, et al. Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis. Autoimmunity. 1995;20:1–7.

    Article  PubMed  CAS  Google Scholar 

  33. Tokay S, Direskeneli H, Yurdakul S, Akoglu T. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford). 2001;40:192–5.

    Article  CAS  Google Scholar 

  34. Lamprecht P, deGroot K, Schnabel A, et al. Anticardiolipin antibodies and antibodies to beta(2)-glycoprotein I in patients with Wegener's granulomatosis. Rheumatology (Oxford). 2000;39:568–70.

    Article  CAS  Google Scholar 

  35. Gupta M, Johann-Liang R, Bussel JB, et al. Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease. Cardiology. 2002;97:180–2.

    Article  PubMed  CAS  Google Scholar 

  36. Yang YH, Huang MT, Lin SC, et al. Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. Clin Exp Immunol. 2000;122:285–90.

    Article  PubMed  CAS  Google Scholar 

  37. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis. Arthritis Rheum. 2008.15;59:561–7.

    Google Scholar 

  38. Burden AD, Tillman DM, Foley P, Holme E. IgA class anticardiolipin antibodies in cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol. 1996;35:411–5.

    Article  PubMed  CAS  Google Scholar 

  39. Klok AM, Geertzen R, Rothova A, et al. Anticardiolipin antibodies in uveitis. Curr Eye Res. 1992;11:209–13.

    Article  PubMed  Google Scholar 

  40. Mankai A, Achour A, Thabet Y, et al.: Anti-cardiolipin and anti-beta 2-glycoprotein I antibodies in celiac disease. Autoimmun Rev. 2011 [Epub ahead of print].

  41. Gabeta S, Norman GL, Gatselis N, et al. IgA Anti-b2GPI Antibodies in patients with autoimmune liver disease. J Clin Immunol. 2008;28:501–11.

    Article  PubMed  CAS  Google Scholar 

  42. Magro CE, Guidolin F, Bezerra NF, et al. Livedo reticularis with ulcers in a pateint with IgA anticardiolipin antibodies. An Bras Dermatol. 2005;80:538–9.

    Article  Google Scholar 

  43. Wilson WA, Morgan Ost C, Barton EN, et al. IgA antiphospholipid antibodies in HTLV-1 associated tropical spastic paraparesis. Lupus. 1995;4:138–41.

    Article  PubMed  CAS  Google Scholar 

  44. Yoon KH, Wong A, Shakespeare T, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003;12:112–6.

    Article  PubMed  CAS  Google Scholar 

  45. Bernardini I, Pugliese L, Pacifico E, et al. IgA anticardiolipin in patients with gastroenteric Tumor. Scholary Research Exchange 2009;1–4.

  46. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39:1466–74.

    Article  PubMed  CAS  Google Scholar 

  47. Lee SS, Cho ML, Joo YS, et al. Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28:520–4.

    PubMed  CAS  Google Scholar 

  48. Danowski A, Kickler TS, Petri M. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. 2006;33:1775–9.

    PubMed  CAS  Google Scholar 

  49. Karpouzas GA, Moran RC, Harris C, Hahn BH. B2-glycoprotein-I IgA antibodies (a-b2GPI IgA Ab) but not the IgG a-B2 and IgG a-cardiolipin listed in Sydney criteria predispose to vascular events in Hispanics with SLE. Arthritis Rheum. 2009;60:S479 [abstract 1276].

    Google Scholar 

  50. • Sweiss NJ, Bo R, Kapadia R, et al. IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One. 2010;5:e12280. An interesting cohort of patients with isolated IgA anti-β2GPI antibodies and the description of clinical associations in patients with SLE.

    Article  PubMed  Google Scholar 

  51. Guerin J, Casey E, Feighery C, Jackson J. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31:109–16.

    Article  PubMed  CAS  Google Scholar 

  52. Bruce IN, Clark-Soloninka CA, Spitzer KA, et al. Prevalence of antibodies to beta2-glycoprotein I in systemic lupus erythematosus and their association with antiphospholipid antibody syndrome criteria: a single center study and literature review. J Rheumatol. 2000;27:2833–7.

    PubMed  CAS  Google Scholar 

  53. Yamada H, Tsutsumi A, Ichikawa K, et al. IgA-class anti-beta2-glycoprotein I in women with unexplained recurrent spontaneous abortion. Arthritis Rheum. 1999;42:2727–8.

    Article  PubMed  CAS  Google Scholar 

  54. Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18:1011–4.

    Article  PubMed  CAS  Google Scholar 

  55. Abinader A, Hanly AJ, Lozada CJ. Catastrophic antiphospholipid syndrome associated with anti-beta-2-glycoprotein I IgA. Rheumatology (Oxford). 1999;38:84–5.

    Article  CAS  Google Scholar 

  56. Boin F, Franchini S, Colantuoni E, et al. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum. 2009;60:2480–9.

    Article  PubMed  Google Scholar 

  57. Staub HL, Franck M, Ranzolin A., et al. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev. 2006:104–6.

  58. Kahles T, Humpich M, Steinmetz H, et al. Phosphatidylserine IgG and beta-2-glycoprotein I IgA antibodies may be a risk factor for ischaemic stroke. Rheumatology (Oxford). 2005;44:1161–5.

    Article  CAS  Google Scholar 

  59. Borges RB, Bodanese LC, Mühlen CA, et al. Anti-beta2-glycoprotein I autoantibodies and metabolic syndrome. Arq Bras Cardiol. 2011;96:272–6.

    Article  PubMed  CAS  Google Scholar 

  60. Serrano A, García F, Serrano M, et al. IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int. 2012;81:1239–44.

    Article  PubMed  CAS  Google Scholar 

  61. Holc I, Hojs R, Cikeš N, et al. Antiphospholipid antibodies and atherosclerosis: insights from rheumatoid arthritis–a five-year follow-up study. Immunobiology. 2011;216:1331–7.

    Article  PubMed  CAS  Google Scholar 

  62. Iverson GM, von Mühlen CA, Staub HL, et al. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun. 2006;27:266–71.

    Article  PubMed  CAS  Google Scholar 

  63. Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: A promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012. [Epub ahead of print]

  64. Martinez-Martinez LA, Aguilar-Valenzuela R, Seif AM, et al. Do clinically relevant IgA-Anti-B2glycoprotein I (anti-B2GPI) Antibodies bind domain IV/V of β2GPI? Arthritis Rheum. 2009;60:S478 [abstract 1274].

    Google Scholar 

  65. Akhter E, Binder W, Shums Z, et al. Utility of anti-phosphatidilserine/prothrombin and IgA Antiphospholipid assays in antiphospholipid syndrome. Arthritis Rheum. 2010;62:S5 [abstract 14].

    Google Scholar 

  66. Pierangeli SS, Liu XW, Barker JH, et al. Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thromb Haemost. 1995;74:1361–7.

    PubMed  CAS  Google Scholar 

  67. Ruiz-Limon P, Romay-Penabad Z, Carrera Marin AL, et al. IgA anti-β2glycoprotein I antibodies are pathogenetic in a mouse model of APS. Arthritis Rheum. 2012;64:S742 [abstract 1731].

    Google Scholar 

  68. •• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86. The updated classification criteria for SLE proposed by the international group SLICC have included for the first time IgA aCL and IgA anti-β2GPI as valid tests for the definition of SLE.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Andreoli is supported by a Research Grant financed by an agreement between the Government of Lombardy and the University of Brescia (“Dote Ricercatore e Dote Ricerca Applicata ai sensi dell’accordo regionale per lo sviluppo del capitale umano nel sistema universitario Lombardo sottoscritto tra Regione Lombardia e Università Lombarde il 20-10-2009, Università degli Studi di Brescia”).

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

Laura Andreoli declares that she has no conflict of interest.

Micaela Fredi declares that she has no conflict of interest.

Cecilia Nalli declares that she has no conflict of interest.

Silvia Piantoni declares that she has no conflict of interest.

Rossella Reggia declares that she has no conflict of interest.

Francesca Dall’Ara declares that she has no conflict of interest.

Franco Franceschini declares that he has no conflict of interest.

Angela Tincani declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy

    Laura Andreoli, Micaela Fredi, Cecilia Nalli, Silvia Piantoni, Rossella Reggia, Francesca Dall’Ara & Angela Tincani

  2. Rheumatology Chair, University of Pavia, Pavia, Italy

    Micaela Fredi, Cecilia Nalli, Silvia Piantoni, Rossella Reggia & Francesca Dall’Ara

  3. Rheumatology and Clinical Immunology, Piazzale Spedali Civili 1, 25123, Brescia, Italy

    Franco Franceschini

Authors
  1. Laura Andreoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Micaela Fredi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cecilia Nalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Silvia Piantoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rossella Reggia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesca Dall’Ara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Franco Franceschini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Angela Tincani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angela Tincani.

Additional information

This article is part of the Topical Collection on Antiphospholipid Syndrome

Rights and permissions

Reprints and permissions

About this article

Cite this article

Andreoli, L., Fredi, M., Nalli, C. et al. Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies. Curr Rheumatol Rep 15, 343 (2013). https://doi.org/10.1007/s11926-013-0343-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-013-0343-1

Keywords

Search

Navigation